233 related articles for article (PubMed ID: 26708105)
21. Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome.
Dahlhaus R; El-Husseini A
Behav Brain Res; 2010 Mar; 208(1):96-105. PubMed ID: 19932134
[TBL] [Abstract][Full Text] [Related]
22. Fragile X Mental Retardation Protein (FMRP) controls diacylglycerol kinase activity in neurons.
Tabet R; Moutin E; Becker JA; Heintz D; Fouillen L; Flatter E; Krężel W; Alunni V; Koebel P; Dembélé D; Tassone F; Bardoni B; Mandel JL; Vitale N; Muller D; Le Merrer J; Moine H
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3619-28. PubMed ID: 27233938
[TBL] [Abstract][Full Text] [Related]
23. 7, 8-Dihydroxyflavone induces synapse expression of AMPA GluA1 and ameliorates cognitive and spine abnormalities in a mouse model of fragile X syndrome.
Tian M; Zeng Y; Hu Y; Yuan X; Liu S; Li J; Lu P; Sun Y; Gao L; Fu D; Li Y; Wang S; McClintock SM
Neuropharmacology; 2015 Feb; 89():43-53. PubMed ID: 25229717
[TBL] [Abstract][Full Text] [Related]
24. Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior.
Dwyer JM; Maldonado-Avilés JG; Lepack AE; DiLeone RJ; Duman RS
Proc Natl Acad Sci U S A; 2015 May; 112(19):6188-93. PubMed ID: 25918363
[TBL] [Abstract][Full Text] [Related]
25. Fragile X Mental Retardation Protein and Dendritic Local Translation of the Alpha Subunit of the Calcium/Calmodulin-Dependent Kinase II Messenger RNA Are Required for the Structural Plasticity Underlying Olfactory Learning.
Daroles L; Gribaudo S; Doulazmi M; Scotto-Lomassese S; Dubacq C; Mandairon N; Greer CA; Didier A; Trembleau A; Caillé I
Biol Psychiatry; 2016 Jul; 80(2):149-159. PubMed ID: 26372002
[TBL] [Abstract][Full Text] [Related]
26. PF-4708671, a specific inhibitor of p70 ribosomal S6 kinase 1, activates Nrf2 by promoting p62-dependent autophagic degradation of Keap1.
Park JS; Kang DH; Lee DH; Bae SH
Biochem Biophys Res Commun; 2015 Oct; 466(3):499-504. PubMed ID: 26381178
[TBL] [Abstract][Full Text] [Related]
27. NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome.
Deacon RM; Glass L; Snape M; Hurley MJ; Altimiras FJ; Biekofsky RR; Cogram P
Neuromolecular Med; 2015 Mar; 17(1):71-82. PubMed ID: 25613838
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation and restoration of translational homeostasis in fragile X syndrome.
Richter JD; Bassell GJ; Klann E
Nat Rev Neurosci; 2015 Oct; 16(10):595-605. PubMed ID: 26350240
[TBL] [Abstract][Full Text] [Related]
29. Synaptic vesicle dynamic changes in a model of fragile X.
Broek JAC; Lin Z; de Gruiter HM; van 't Spijker H; Haasdijk ED; Cox D; Ozcan S; van Cappellen GWA; Houtsmuller AB; Willemsen R; de Zeeuw CI; Bahn S
Mol Autism; 2016; 7():17. PubMed ID: 26933487
[TBL] [Abstract][Full Text] [Related]
30. A Synaptic Perspective of Fragile X Syndrome and Autism Spectrum Disorders.
Bagni C; Zukin RS
Neuron; 2019 Mar; 101(6):1070-1088. PubMed ID: 30897358
[TBL] [Abstract][Full Text] [Related]
31. Changes in insulin-like growth factor signaling alter phenotypes in Fragile X Mice.
Wise TL
Genes Brain Behav; 2017 Feb; 16(2):241-249. PubMed ID: 27643697
[TBL] [Abstract][Full Text] [Related]
32. Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice.
Cogram P; Alkon DL; Crockford D; Deacon RMJ; Hurley MJ; Altimiras F; Sun MK; Tranfaglia M
Sci Rep; 2020 Oct; 10(1):18058. PubMed ID: 33093534
[TBL] [Abstract][Full Text] [Related]
33. Excitatory neuron-specific suppression of the integrated stress response contributes to autism-related phenotypes in fragile X syndrome.
Hooshmandi M; Sharma V; Thörn Perez C; Sood R; Krimbacher K; Wong C; Lister KC; Ureña Guzmán A; Bartley TD; Rocha C; Maussion G; Nadler E; Roque PM; Gantois I; Popic J; Lévesque M; Kaufman RJ; Avoli M; Sanz E; Nader K; Hagerman RJ; Durcan TM; Costa-Mattioli M; Prager-Khoutorsky M; Lacaille JC; Martinez-Cerdeno V; Gibson JR; Huber KM; Sonenberg N; Gkogkas CG; Khoutorsky A
Neuron; 2023 Oct; 111(19):3028-3040.e6. PubMed ID: 37473758
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation.
Lee SJ; Yang EK; Kim SG
Mol Pharmacol; 2006 Jul; 70(1):415-25. PubMed ID: 16611854
[TBL] [Abstract][Full Text] [Related]
35. Crystal structures of the S6K1 kinase domain in complexes with inhibitors.
Niwa H; Mikuni J; Sasaki S; Tomabechi Y; Honda K; Ikeda M; Ohsawa N; Wakiyama M; Handa N; Shirouzu M; Honma T; Tanaka A; Yokoyama S
J Struct Funct Genomics; 2014 Sep; 15(3):153-64. PubMed ID: 25078151
[TBL] [Abstract][Full Text] [Related]
36. Structure-based identification of potential inhibitors of ribosomal protein S6 kinase 1, targeting cancer therapy: a combined docking and molecular dynamics simulations approach.
Alam A; Khan MS; Mathur Y; Sulaimani MN; Farooqui N; Ahmad SF; Nadeem A; Yadav DK; Mohammad T
J Biomol Struct Dyn; 2024 Jul; 42(11):5758-5769. PubMed ID: 37365756
[TBL] [Abstract][Full Text] [Related]
37. eIF3 controls cell size independently of S6K1-activity.
Schipany K; Rosner M; Ionce L; Hengstschläger M; Kovacic B
Oncotarget; 2015 Sep; 6(27):24361-75. PubMed ID: 26172298
[TBL] [Abstract][Full Text] [Related]
38. Autism and fragile X syndrome.
Yu TW; Berry-Kravis E
Semin Neurol; 2014 Jul; 34(3):258-65. PubMed ID: 25192504
[TBL] [Abstract][Full Text] [Related]
39. BDNF in fragile X syndrome.
Castrén ML; Castrén E
Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
[TBL] [Abstract][Full Text] [Related]
40. Behavioral Phenotype of Fmr1 Knock-Out Mice during Active Phase in an Altered Light/Dark Cycle.
Saré RM; Levine M; Smith CB
eNeuro; 2016; 3(2):. PubMed ID: 27294193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
